Market Cap
$56.0M
TELA
TELA Bio, Inc.
$1.19 ▼ -4.80%
Prev close $1.25Market cap$56.0M
ConsensusStrong Buy
12-mo target$2.08 (+75.1%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)3 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on TELA right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (82%)
Inst. Holders
26 funds
Inst. Value
$2.3M
Inst. Activity
2 buys / 3 sells
Insider Activity
$186.0K buy / $0.00 sell
Insider Net $
$186.0K
SEC Reports
10
Press Releases
2
Price chart 30d +58.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 17, 2026 Insider
Capper Joseph H bought 25,000 shares
Director @ $1.22 ($30.5K)
Sep 16, 2026 Insider
Capper Joseph H bought 50,000 shares
Director @ $1.17 ($58.3K)
Sep 15, 2026 Insider
Aug 31, 2026 SEC Capper Joseph H bought 50,000 shares
Director @ $1.06 ($52.9K)
TELA Bio announced a strategic cost reduction initiative including a 20% workforce reduction (201 to 160 employees) and
8-K — Impact 6/10
Aug 31, 2026 leadership
Aug 11, 2026 SEC TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency pr
TELA Bio reported Q2 2026 revenue of $19.3M, a 4% decline YoY, and an EPS of -$0.20, missing consensus estimates of -$0.
8-K — Impact 7/10
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — TRIM
74,790 shares ($56.1K)
Jun 30, 2026 Inst.
RAYMOND JAMES FINANCIAL INC — ADD
67,700 shares ($50.8K)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
82% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 25, 2026 | Craig-Hallum | INITIATE | Buy | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Aug 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Jul 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Jun 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% |
Price targets
Where 6 covering analysts think TELA trades over the next 12 months.
$2.08 +75.1% upside Strong Buy
Current$1.19 Low$1.00 Median$2.00 High$3.00 6 analysts
$1.00$3.00
Analyst rating Strong Buy· 1.5/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 0 bullish, 2 bearish, 3 mixed, 5 neutral · avg impact 4.0/10.Plus 2 press releases.
MIXED8-K6/10
TELA Bio announced a strategic cost reduction initiative including a 20% workforce reduction (201 to
Aug 31, 2026
BEARISH8-K7/10
TELA Bio reported Q2 2026 revenue of $19.3M, a 4% decline YoY, and an EPS of -$0.20, missing consens
Aug 11, 2026
NEUTRAL32/10
Joseph Capper filed a Form 3 initial statement of beneficial ownership with TELA Bio, Inc., indicati
Jun 11, 2026
NEUTRAL32/10
Guido Neels filed an initial statement of beneficial ownership (Form 3) with TELA Bio, Inc., indicat
Jun 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 31, 2026
leadership
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses
Aug 10, 2026
earnings_calendar
TELA Q2 2026 Earnings Scheduled — 2026-08-10
May 12, 2026
earnings
TELA Bio Reports First Quarter 2026 Financial Results
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on
May 12, 2026
earnings_calendar
TELA Q1 2026 Earnings Scheduled — 2026-05-12
Apr 30, 2026
earnings
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.15 | $-0.21–$-0.13 | 18.4% | -2.0% | 3↑ 2↓ | $0.0B | 6 |
| Next Q | $-0.12 | $-0.16–$-0.10 | 29.4% | +10.4% | 4↑ 1↓ | $0.0B | 6 |
| Current FY | $-0.69 | $-0.76–$-0.64 | 16.9% | +1.4% | 1↑ 4↓ | $0.1B | 6 |
| Next FY | $-0.45 | $-0.52–$-0.40 | 34.8% | +13.8% | 5↑ 0↓ | $0.1B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.155 | — |
| 7d ago | $-0.158 | +0.003 |
| 30d ago | $-0.152 | -0.003 |
| 60d ago | $-0.150 | -0.005 |
| 90d ago | $-0.150 | -0.005 |
Institutional ownership
Which big funds own TELA (from quarterly 13F filings) and who is adding or trimming.
26 institutional holders with $2.3M total value (3,019,300 shares) as of 2026-Q2. Top holders: ROYAL, VANGUARD, GEODE. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 59 | $0.00 | 0.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,568,218 | $1.2M | 52.0% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 389,223 | $292.0K | 12.9% | ADD +25.9% |
| BlackRock, Inc. | 374,516 | $280.9K | 12.4% | — |
| VANGUARD FIDUCIARY TRUST CO | 213,138 | $159.9K | 7.1% | — |
| NORTHERN TRUST CORP | 74,790 | $56.1K | 2.5% | TRIM -57.1% |
| RAYMOND JAMES FINANCIAL INC | 67,700 | $50.8K | 2.2% | ADD +36.2% |
| STATE STREET CORP | 63,383 | $47.5K | 2.1% | — |
| RENAISSANCE TECHNOLOGIES LLC | 58,100 | $43.6K | 1.9% | TRIM -59.1% |
| PNC FINANCIAL SERVICES GROUP, INC. | 53,612 | $40.2K | 1.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORTHERN TRUST CORP | TRIM | 174,398 | 74,790 | -57.1% | $56.1K |
| RAYMOND JAMES FINANCIAL INC | ADD | 49,700 | 67,700 | +36.2% | $50.8K |
| UBS Group AG | NEAR_EXIT | 1,059,524 | 33,466 | -96.8% | $25.1K |
| CITIGROUP INC | NEAR_EXIT | 750,000 | 1,774 | -99.8% | $1.3K |
| SIMPLEX TRADING, LLC | DOUBLED | 143 | 1,276 | +792.3% | $957.00 |
| UBS Group AG | TRIM | 1,500,469 | 1,059,524 | -29.4% | $656.9K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 361,498 | 455,059 | +25.9% | $282.2K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 128,700 | 52,600 | -59.1% | $32.6K |
| SIMPLEX TRADING, LLC | DOUBLED | 3 | 143 | +4666.7% | $88.00 |
| UBS Group AG | DOUBLED | 216,802 | 1,500,469 | +592.1% | $1.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 50 transactions. Net $186.0K — $186.0K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Capper Joseph H | Director | BUY | 25,000 | $1.22 | $30.5K |
| Sep 16, 2026 | Capper Joseph H | Director | BUY | 50,000 | $1.17 | $58.3K |
| Sep 15, 2026 | Capper Joseph H | Director | BUY | 50,000 | $1.06 | $52.9K |
| Sep 14, 2026 | Capper Joseph H | Director | BUY | 25,000 | $1.02 | $25.5K |
| Aug 17, 2026 | Getz Heather C | Chief Executive Officer | BUY | 12,500 | $0.6649 | $8.3K |
| Aug 14, 2026 | Getz Heather C | Chief Executive Officer | BUY | 15,000 | $0.6978 | $10.5K |
| Aug 3, 2026 | Getz Heather C | Chief Executive Officer | AWARD | 500,000 | — | — |
| Aug 3, 2026 | Getz Heather C | Chief Executive Officer | AWARD | 1,365,000 | — | — |
| Aug 3, 2026 | Getz Heather C | Chief Executive Officer | AWARD | 1,005,000 | — | — |
| Jul 15, 2026 | Capper Joseph H | Director | AWARD | 6,227 | $0.7850 | $4.9K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TELA.
Shares short
550,824
Settlement Sep 15, 2026
Change vs prior
+43.2%
Semi-monthly cycle
Days to cover
2.2
At avg daily volume
Of shares outstanding
≈1.2%
Estimate — not % of float
All TELA filing & press-release reports (12)
- 8-K reportAug 31, 2026
- 8-K reportAug 11, 2026
- 3 reportJun 11, 2026
- 3 reportJun 11, 2026
- 3 reportJun 11, 2026
- 3 reportJun 11, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- 8-K reportApr 30, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportMar 24, 2026
- PRESS-RELEASE reportMar 10, 2026